Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05474417 · ClinicalTrials.gov registry record

The Effects of the CF Carrier State on the Kidneys and Pancreas

A clinical trial of Kidney Diseases and Pancreatic Disease, sponsored by Philip Polgreen.

Recruiting
Registry status
1,250
Enrollment target
1
Study location

NCT05474417 is a study of Kidney Diseases and Pancreatic Disease that is actively recruiting participants, run by Philip Polgreen. The registered enrollment target is 1,250 participants, below the 1,753-participant average among 38 other Kidney Diseases trials with a reported enrollment target (29% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05474417, a study of Kidney Diseases and Pancreatic Disease, is actively recruiting participants, sponsored by Philip Polgreen.

RECRUITING
Registry status
1,250 participants
Enrollment target
1
Study location

Study Summary

The overarching hypothesis is that CF carriers are at increased risk for developing most of the extrapulmonary conditions associated with CF compared to the general population. Specifically, it is hypothesized that this pilot data will detect subclinical evidence of pancreatic and kidney disorders among CF carriers. This will be determined by bringing CF carriers and controls to the CRU for one visit where they will answer survey questions and undergo laboratory testing. Additionally, they will collect urine and stool samples at home that will be sent to outside laboratories for testing.

Study Locations (1)

Iowa

  • University of Iowa Hospitals and Clinics - Iowa City

Trial Details

FieldValue
Enrollment Target 1,250 participants
Start Date 2021-12-20
Est. Completion 2026-07

Sponsor

Philip Polgreen

3 total trials

What the Registry Record Tells You About NCT05474417

The ClinicalTrials.gov registry entry for NCT05474417 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,753-participant average among 38 other Kidney Diseases trials with a reported enrollment target (29% lower). The listed sponsor is Philip Polgreen, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Kidney Diseases appearing as the primary indexed condition, and to 0 interventions.

NCT05474417 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.

Frequently Asked Questions

What is clinical trial NCT05474417 about?

NCT05474417 is a clinical study titled "The Effects of the CF Carrier State on the Kidneys and Pancreas". The overarching hypothesis is that CF carriers are at increased risk for developing most of the extrapulmonary conditions associated with CF compared to the general population. Specifically, it is hypothesized that this pilot data will detect subclinical evidence of pancreatic and kidney disorders a...

What is the current status of trial NCT05474417?

This trial is currently recruiting. The enrollment target is 1,250 participants. The study started on 2021-12-20. Estimated completion is 2026-07.

What conditions does trial NCT05474417 study?

This clinical trial studies the following conditions: Kidney Diseases, Pancreatic Disease, Carrier State.

Who is sponsoring clinical trial NCT05474417?

This trial is sponsored by Philip Polgreen, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05474417 being conducted?

This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Kidney Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.